Image courtesy of Abbott

New Real-World Data Show That Abbott’s New Freestyle Libre System Delivers Positive Health Outcomes

Originally published on Abbott.com

New Real-World Data Show That Abbott’s New Freestyle Libre System Delivers Positive Health Outcomes For People with Type 1 and Type 2 Diabetes

– Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world

– People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology

Abbott announced that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid. The new data show that users of the FreeStyle Libre system have improved glucose control,iii increased time in target glucose range,iii and decreased time in hyperglycemiaiv (high glucose levels) and hypoglycemiaiv (low glucose levels), as well as reduced HbA1Ci,ii (average glucose levels over a three month period).ii 

“As the world leader in sensor-based glucose monitoring with more than two million users, Abbott’s FreeStyle Libre system has an unmatched body of real-world evidence supporting its clinical benefits,” said Mahmood Kazemi, M.D., divisional vice president, global medical and scientific affairs, and chief medical officer, Diabetes Care, Abbott. “Time and time again, we’ve seen meaningful data that reaffirm our technology’s direct impact in achieving better health outcomes for people with diabetes – and the findings at ATTD underscore how we’re continuing to transform people’s lives.”

The following abstracts are being presented at ATTD:

Improving HbA1c Control in People with Type 1 or Type 2 Diabetes Using FreeStyle Libre

  • People living in Germanywith Type 1 or Type 2 diabetes on insulin show a sustained reduction in HbA1c over 12 months following use of the FreeStyle Libre system,ii which indicates that FreeStyle Libre users had an improved HbA1c that was maintained over a substantial period of time. The American Diabetes Association recommends an HbA1C goal of less than 7% for adults with diabetes.v People with Type 1 diabetes using the FreeStyle Libre system with a baseline HbA1c greater than 7.5% showed an average reduction of 1.4%, and people with Type 2 diabetes showed an average reduction of 1.2%. An HbA1c level that is reduced by almost 1% is linked to an overwhelming reduction in long-term complications of diabetes by 30% according to landmark studies.vi

Real-World Study of FreeStyle Libre System Among Adults with Type 1 and Type 2 Diabetes within the Sweden National Diabetes Register

  • Notable dataifrom Sweden’s National Diabetes Register conclude that people with Type 1 and Type 2 diabetes significantly reduced their HbA1c when they used the FreeStyle Libre system for three to nine months. A reduction of HbA1c of 0.44% for people with Type 1 and 0.67% for people with Type 2 were observed with first-time users of FreeStyle Libre system.

Canadian Real-World Analysis of FreeStyle Libre and Glycemic Control 

  • Expanded analysisiii of real-world data from Canadademonstrate that higher frequency of scanning is associated with increased time in target glucose range (hours per day spent in between 70-180 mg/dLvii) and decreased hypoglycemia. Greater time in range has been linked to more stable glucose control, which could lead to fewer complications. FreeStyle Libre users who scanned at the lowest frequency (3.3 scans per day) spent 54.6% time in range, and users with the highest scanning frequency (29.3 scans per day) spent 66.7% time in range.This analysis, in addition to previous real-world findings,viii consistently show a strong association between FreeStyle Libre users who scan more frequently and overall improved glucose control.

Continuous Glucose Monitoring (CGM) Use in the U.S. is Associated with Reduction in Acute Diabetes Complications, Even with Prior Low Test Strip Use

  • More than 12,000 people with diabetes using a CGM for the first time, including the FreeStyle Libre system, experienced a significant reduction in acute diabetes complicationsiv— even in people with diabetes that have a history of self-monitoring of blood glucose (SMBG) using less than four test strips per day.ixPeople with Type 1 diabetes experienced a significant reduction in acute diabetes complications of 44% after CGM usage.iv For people with Type 2 diabetes, there was a significant reduction of 51%.iv

Abbott’s FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.x Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S.

About FreeStyle Libre System
Abbott’s FreeStyle Libre system, the world-leading sensor-based glucose monitoring technology,xi is designed to change how people with diabetes measure their glucose levels and ultimately help them achieve better health outcomes.xii The system reads glucose levels through a sensor that can be worn on the back of the upper arm, eliminating the need for finger sticks.xiii

For the U.S., important safety information: https://www.freestylelibre.us/safety-information.html

 

Latest News

ADP Preparedness Toolkit

Originally posted on ADP LinkedIn Find FAQs, checklists, webcasts, and the resources to help you protect and manage your workforce in the ADP Coronavirus Disease (COVID-19) Employer Preparedness Toolkit: https://bit.ly/2xuM2jW

EY Named a Leader in Managed Security Services and Professional Security Services in Asia-Pacific in Two Studies by IDC

Originally posted on EY.com EY is a leader in Asia-Pacific professional security services among 17 vendors EY has been recognized by IDC as a leader in two of its studies: IDC MarketScape: Asia/Pacific Managed Security Services 2020 Vendor Assessment, and IDC MarketScape: Asia/Pacific Professional Security Services – Advisory, Assessment, and Awareness 2020…

March 2020 ADP National Employment Report®, ADP Small Business Report® and ADP National Franchise Report® to be Released on Wednesday, April 1, 2020

Originally posted on ADP.com : ADP Research Institute® will release the March findings of the ADP National Employment Report, ADP Small Business Report and ADP National Franchise Report on Wednesday, April 1, 2020 at 8:15 a.m. ET. Due to the important contribution that small businesses make to economic growth, ADP Research Institute issues the ADP Small Business Report independently of the ADP National Employment Report. …

Combatting Human Trafficking: How Hilton and Marriott Address a Global Human Rights Issue

It is estimated that anywhere from 20 to 40 million people are trapped in modern slavery worldwide. The fragmented, transient and relatively anonymous nature of hotels has made them critical sites for the trafficking of humans — typically for forced labor or sexual exploitation. But the hospitality industry has taken…

Dow Commits $3 million to Aid COVID-19 Relief Efforts and Adjusts Manufacturing Processes to Produce Hand Sanitizer

Originally posted on Dow.com Dow announced a commitment of $3 million to help fund COVID-19 relief efforts with donations going towards global relief organizations, as well as non-profits in communities where Dow operates. In addition, the Company announced it has begun producing hand sanitizer at its manufacturing site in Stade, Germany, and…

EY COVID-19 Business Continuity Plan: Five Ways to Reshape

Originally posted on EY LinkedIn and  EY.com  EY Responding to COVID-19 COVID-19 is an unfolding event bringing uncertainty to every business. To help you navigate through these unprecedented times, here you’ll find the most relevant EY insights on responding to volatility and building enterprise resilience. Global companies have to be predictive…

Wells Fargo Announces Aid for Customers and Communities Impacted by COVID-19

Comprehensive response includes suspending residential foreclosure sales, fee waivers and acceleration of $175 million in donations to help the most vulnerable Originally published on newsroom.wf.com. Wells Fargo & Company (NYSE: WFC) today announced additional comprehensive steps to help customers, communities and employees grappling with the impact of COVID-19. The company…

Cox Commits up to $5M for COVID-19 Testing

Originally posted on Cox.com The James M. Cox Foundation announced its commitment to provide up to $5 million to Emory Healthcare for purchasing COVID-19 testing equipment. In response to the coronavirus crisis, Emory and Cox are taking the lead with significant action to support the community. The equipment is currently…